Bladder cancer detection reagent and application thereof
By designing specific primer combinations to detect METTL3 gene expression and combining them with real-time PCR technology, we provide bladder cancer detection reagents and kits, solving the problem of difficult early diagnosis of bladder cancer and achieving highly sensitive early screening and monitoring.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-26
- Publication Date
- 2026-03-10
AI Technical Summary
Bladder cancer often presents with subtle early symptoms, develops rapidly, and is difficult to diagnose due to pathological findings. As a result, most patients are diagnosed at an advanced stage, and the recurrence rate is high. Current technology lacks effective early screening or prognostic monitoring methods.
We designed specific primer combinations to detect the expression level of the METTL3 gene, and combined them with real-time PCR technology to detect the m6A methylation modification process in bladder cancer samples, providing bladder cancer detection reagents and kits for auxiliary diagnosis.
It achieves specific and highly sensitive detection of bladder cancer, with strong anti-interference ability, enabling early screening and monitoring of bladder cancer, reducing diagnostic difficulties and recurrence rates.